Indication intelligence, analysis and sector perception

RegMed Investors’ (RMi) closing bell, share pricing as musical chairs

May 23, 2017 6:08pm

If you are not listening in on this market, you might not hear the music at all

And if you don't hear the music, how can you expect to find a sector chair when the music stops?

Closes are all about what will happen in the next morning’s session - it's time to know ...!

Pre-open indications: 4 hit and 2 miss

Who do you call for “share side” assistance? It’s not AAA … try RMi

As the leading voice of cell therapy investors; I am not always a doom and gloom reporter but a man who has been “there” with the gray hair and a readership following with real numbers to prove it!

I answer one question, in which company should investors commit and keep their money

RMi’s daily and continual “reads” of the goings-on of the SCG&RT sector can improve investor’s and trader’s odds - just because a stock underperforms the market doesn’t mean you have to lose money.

Henry’omics:

From the pre-open’s investor’s newsletter … “Insight is interpreting perception. Insight is also about putting into context what is relevant to expectation fulfillment.”

Reiterating, “The take-away, don’t dwell on what’s happened but, learn the lesson of investing in those who define and meet short-term expectation. Spare the sell call, ruin the portfolio.”

On Tuesday, spikes in volatility created buying opportunities because the fundamentals have started to align and become strong

I am on the fence about the morning session - I percieve .... WEAKNESS!

Pre-open indications: 4 hit and 2 miss

Applied Genetic Technologies (AGTC) closed down -$0.05 – hit;
Bellicum Pharmaceuticals (BLCM) closed up +$0.09 – miss;
bluebird bio (BLUE) closed up +$1.40 – hit;
Kite Pharma (KITE) closed down -$0.61 – miss;
Sangamo (SGMO) closed up +$0.75 – hit;
Vericel (VCEL) closed up + $0.05 – hit;

Daily analytics:

U.S. equities closed DOWN on Monday … with the DOW closing UP +0.21% (+43.08) as the NASDAQ also closed UP +0.08% (+5.09) …

… The CBOE Volatility Index (VIX) widely considered the best gauge of fear in the market, traded at 10.8.

· Monday’s 10.9 followed Friday’s 12.2, Thursday’s at 14.6 down -5.97%, Wednesday ‘s 15.59 – a 44% increase and last Tuesday’s 10.56;

Welcome to another day of the sector’s roller coaster …

… The iShares Russell 2000 (IWM) indicated a positive +0.21% at the pre-open and closed UP +0.20% after Monday’s +0.30% after Friday’s +0.48%, Thursday +0.36, Wednesday’s -2.70% and last Tuesday’s +0.04%

… The iShares NASDAQ Biotechnology (IBB) did NOT indicate in the pre-open and closed DOWN -0.12%, following Monday’s +0.68, Friday’s -0.62, Thursday’s +1.28, Wednesday -2.27% and last Tuesday’s +0.40%

The advance/decline line scenario of 43 SCGT & RT covered companies:

· The open was negative with an A/DL of 18/23 and 2 flats;

· The mid-day was neutral with an A/DL of 20/20 and 3 flats;

· The close was positive with an A/DL of 25/15 and 3 flats;

The count - decliners versus gainers: look at the differences in the spreads and advance/decline lines:

· Tuesday’s decliners ranged from -0.24% <BCLI> to -8.54% <ISCO> in 15 equities;

· Monday’s decliners ranged from -0.45% <BLFS> to -21.67% <BSTG> in 21 equities;

· Friday’s decliners ranged from -0.17% <BSTG> to -6.78% <BLUE> in 15 equities;

· Thursday’s decliners ranged from -0.32% <KOOL> to -6.42% <AGTC> in 13 equities;

· Wednesday’s decliners ranged from -0.47% <BLFS> to -9.23% <OSIR> in 39 equities;

· Last Tuesday’s decliners ranged from -0.19% <ONCE> to -23.27% <IMUC> in 19 equities;

Versus

· Tuesday’s gainers ranged from +0.51% <OSIR> to +13.62% <BSTG> in 25 equities;

· Monday’s gainers ranged from +0.28% <RGNX> to +12.77% <OPXA> in 19 equities;

· Friday’s gainers ranged from +0.01% <HSGX> to +10.66% <QURE> in 26 equities;

· Thursday’s gainers ranged from +0.35% <MDXG> to +16.46% <CUR> in 25 equities;

· Wednesday’s gainers ranged from +0.72% <AXGN> to +6.83% <ISCO> in 4 equities;

· Last Tuesday’s gainers ranged from +0.06% <BLUE> to +10.33% <OPXA> in 23 equities;

Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice.

Whether information or intelligence is good, bad or somewhere in between; I put into context what is relevant and useful for investors. All investments are subject to risks. Investors should consider investment objectives.

Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.

35 companies, 1 interpreter!

Insight, foresight and recommendation

What's Happening Today

8 hours 10 min ago
RegMed Investors’ (RMi) pre-open: market, market and the sector pullbacks are driven by Israel retaliation against Iran tempered expectations for a rate cut

My motto … never leave an investor uninformed! I say today what others won’t, so you can do what others can’t.

My name is Henry McCusker; I endorse these opinions under my own name and with a subscription based membership.

Do you have an opinion you would like to share with us? We would like to hear from you.

Please e-mail us at hwm@regmedinvestors.com.

Editor and Publisher ... Henry McCusker enters his tenth (10th) year at RegMed Investors with past experience in sell-side analysis, buy-side management, corporate management and due diligence.

RegMed Investors (RMi) or Regmedinvestors.com content is the intellectual property of Henry McCusker. Any copying, republication or redistribution of RMI’s content, including by framing or similar means, is expressly prohibited without the prior written consent of Scimitar; who also shall not be liable for any errors or delays in content, or for any actions taken in reliance thereon. For additional information on other Scimitar media services or reposting please email hwm@regmedinvestors.com.

The information included above as well as individual companies and/or securities mentioned should be construed as guidance in RMi reviews.

The facts stated and the opinions given in this publication are based on data and information considered to be reliable and have been carefully worked into my qualitative analyses and prognoses. However, no guarantee can be given as to their fairness, accuracy or completeness.

Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.